Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Basel, August 7, 2025 – Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines, today presents its financial results for the first half of 2025. Growth in this document is shown at constant currencies (CC)[1] unless stated otherwise. FINANCIAL RESULTS  H1 2025H1 2024changeUSD mUSD mUSD %CC %CGR %[2]      Net sales5,2325,0474%4%6% Generics3,7363,7041%1%2% Biosimilars1,4961,34311%12%17%       ...

Core Insights - GAM Holding AG is now fully focused on growth with new investment partnerships and leadership in place, marking a significant transformation in its business strategy [1][6][20] Financial Performance - The underlying pre-tax loss for H1 2025 was CHF 34.1 million, slightly higher than the CHF 33.2 million loss in H1 2024, primarily due to lower net fee and commission income [4] - GAM reported an IFRS net loss after tax of CHF 40.7 million, which includes CHF 6.3 million of reorganisation and other charges [7] - Assets under Management (AuM) stood at CHF 12.7 billion as of 30 June 2025, down from CHF 16.3 billion at the end of 2024, with outflows driven by changes in the European Equity investment team [16][17] Strategic Initiatives - GAM has completed its transformation and is entering a new phase focused on sustainable growth, innovation, and client-centric excellence [6] - The company has enhanced its investment platform with the establishment of a new European Equity team and partnerships with Swiss Re and Gramercy for Cat Bond strategies and Emerging Market Debt strategies, respectively [12][16] - GAM's distribution leadership has been strengthened with new senior hires and the return of Tim Rainsford as Group Chief Distribution Officer [12] Investment Performance - GAM continues to deliver strong investment performance, with 73% of Investment Management AuM outperforming their three-year benchmark and 74% outperforming their five-year benchmark as of 30 June 2025 [10][14] - GAM has also outperformed its peer group, with 55% of Investment Management AuM outperforming their three-year Morningstar peer group and 76% outperforming their five-year peer group [14][15] Awards and Recognition - GAM has received multiple awards, including LSEG Lipper's 2025 Best Overall Investment Group across Europe over three years and the PAM Award 2025 for Investment Performance – Growth Portfolios [12]

Core Viewpoint - Investors in Sable Offshore Corp. have until September 26, 2025, to file lead plaintiff applications in a securities class action lawsuit due to alleged failure to disclose material information during the class period [1][3]. Group 1: Lawsuit Details - The lawsuit against Sable Offshore Corp. and certain executives is based on violations of federal securities laws for not disclosing material information during the class period from May 19, 2025, to June 3, 2025 [1][3]. - The case is identified as Johnson v. Sable Offshore Corp., et al., No. 25-cv-6869 [5]. Group 2: Impact on Stock Price - Following the disclosure of a temporary restraining order that prohibits Sable Offshore from restarting oil transportation through the Las Flores Pipeline System, the company's share price fell by $0.94, or 3.91%, closing at $23.10 on June 4, 2025 [4]. Group 3: ClaimsFiler Information - ClaimsFiler is a service aimed at helping retail investors recover funds from securities class action settlements, providing resources for investors to register, upload portfolio data, and seek legal evaluations [6].

Core Insights - Corteva reported strong Q2 2025 earnings, exceeding analyst expectations with a Non-GAAP EPS of $2.20 and GAAP revenue of $6.46 billion, reflecting significant year-over-year growth [1][2] - The company raised its full-year 2025 financial outlook, driven by solid performance in both Seed and Crop Protection segments [1][11] Financial Performance - Non-GAAP EPS was $2.20, surpassing the consensus estimate of $1.89 [2] - GAAP revenue reached $6.46 billion, exceeding the estimate of $6.27 billion and marking a 5.7% increase from Q2 2024 [2] - Seed net sales were $4.54 billion, a 4.8% increase year-over-year, while Crop Protection net sales rose to $1.92 billion, up 8.0% [2][5][6] Business Segments - The Seed segment's growth was driven by higher volumes and prices, particularly in North America, where corn seed sales increased by 5% [5][7] - Crop Protection sales volume increased by 11%, although pricing decreased by 2%, primarily due to market pressures in Latin America [6][12] Regional Performance - North America was the largest contributor, with seed sales of $3.95 billion and Crop Protection sales of $675 million [7] - EMEA saw an 11% increase in net sales, while Asia Pacific achieved a 5% rise [7] Strategic Focus and Innovation - Corteva emphasized innovation, planning approximately 500 new product launches for 2025, including nearly 300 new seed hybrids [8][9] - The company is also focusing on supply chain improvements and cost productivity benefits [9][10] Future Outlook - The revised full-year 2025 guidance includes net sales of $17.6 billion to $17.8 billion and operating EBITDA (non-GAAP) of $3.75 billion to $3.85 billion [11] - Management highlighted strong demand for corn and ongoing expansion efforts for hybrid wheat and biological crop protection solutions [11]

Core Insights - Steris reported Q1 FY2026 earnings, showing solid year-over-year growth but falling short of analyst expectations for both revenue and adjusted EPS [1][2] - Revenue (GAAP) was $1,391.1 million, below the estimate of $1,447.8 million, while adjusted EPS was $2.34 compared to the consensus estimate of $2.47 [1][2] - Increased tariffs and higher employee benefit costs offset foreign currency gains, leading to an unchanged adjusted earnings outlook despite a raised revenue forecast [1][9] Financial Performance - Non-GAAP EPS for Q1 FY26 was $2.34, a 15.3% increase from $2.03 in Q1 FY25 [2] - GAAP revenue increased by 8.7% year-over-year, from $1,279.5 million in Q1 FY25 to $1,391.1 million [2] - Free cash flow (non-GAAP) rose by 66.8% to $326.5 million compared to $195.7 million in Q1 FY25 [2] Segment Performance - The Healthcare segment generated $974.7 million in revenue, an 8.2% increase from $901.2 million in Q1 FY25 [2][5] - The Applied Sterilization Technologies (AST) segment saw a 12.6% revenue increase, driven by a 12% growth in services and a 46% increase in capital equipment sales [5] - Life Sciences revenue grew by 5.2%, supported by a 53.8% rise in backlog compared to Q1 FY25, indicating strong future demand [5] Operational Developments - Income from operations (GAAP) increased by 32.6% year-over-year, driven by higher pricing and operational productivity [6] - Cash flow from operations rose to $420.0 million, a 38% increase from $303.7 million in Q1 FY25 [6] - Inventory increased by $59.9 million, indicating investments for future growth [6] Strategic Focus - Steris is focusing on expanding its service business and managing global supply chain challenges [4] - The company emphasizes compliance with healthcare regulations and innovation in sterilization technologies [4] - Management raised the revenue growth forecast for FY2026 from 6-7% to 8-9%, driven by favorable foreign currency shifts [9] Cost Challenges - Tariff-related costs are projected to rise from $30 million to $45 million annually, impacting profitability [7] - Labor and employee healthcare costs continue to increase, affecting overall margins [7] - R&D expenses increased to $26.4 million, reflecting ongoing investment in future offerings [7]

Core Insights - Montauk Renewables reported Q2 2025 financial results with revenue of $45.1 million, exceeding analyst expectations, but faced profitability challenges with an EPS of $(0.04) due to higher operating expenses and lower RIN prices [1][5][7] Financial Performance - Revenue (GAAP) increased by 4.1% year-over-year from $43.3 million in Q2 2024 to $45.1 million in Q2 2025, surpassing the estimate of $44.4 million [2][5] - Adjusted EBITDA declined by 27.7% to $5.0 million from $7.0 million in Q2 2024 [7] - The company sold 11.1 million RINs, an increase of 10.5% from 10.0 million in Q2 2024, but the average realized price per RIN fell by 22.4% to $2.42 from $3.12 in Q2 2024 [5][6] Operational Highlights - RNG production remained stable at 1.4 million MMBtu, showing no growth compared to the previous year [6] - Operating and maintenance costs for RNG facilities rose by 22.0% to $17.0 million, attributed to scheduled maintenance and operational improvements [6] - Total operating expenses increased by 11.8%, leading to an operating loss of $(2.4) million and a net loss of $(5.5) million compared to $(0.7) million in Q2 2024 [7] Regulatory and Market Challenges - Revenue recognition delays occurred due to the EPA's new Biogas Regulatory Reform Rule, affecting the sale of approximately 3.0 million RINs [8] - The Renewable Electricity Generation segment produced 42,000 megawatt hours, down from 45,000 in Q2 2024, with operating costs nearly flat year-over-year [8] Strategic Developments - Montauk completed construction of a second RNG processing facility at its Apex site, enhancing future capacity [9] - A 10-year power purchase agreement was signed for the North Carolina agricultural RNG project, securing an average price of $48 per megawatt hour [9] - A new joint venture, GreenWave Energy Partners, LLC, was established to facilitate future RNG transportation and utilization [9] Future Guidance - The company reaffirmed its full-year 2025 guidance, expecting RNG revenue between $150 million and $170 million and RNG production between 5.8 million and 6.0 million MMBtu [10]

Group 1 - The Q2 earnings season has been particularly difficult, with investors driving down shares of most companies despite generally strong results that contradict a challenging macroeconomic environment [1] - This period is viewed as an excellent opportunity for investors to engage in opportunistic stock-picking [1] - The analyst has extensive experience covering technology companies and has been involved with various themes shaping the industry, contributing regularly to Seeking Alpha since 2017 [1]

Financial Performance - VEON reported a revenue growth of 5.9% year-on-year to USD 1,087 million in the second quarter of 2025, with local currency growth at 11.2% YoY, surpassing the average inflation rate of 8.6% in its operating countries [2][9] - Direct digital revenues increased by 56.6% YoY in reported currency and 62.4% YoY in local currency, accounting for 16.5% of total revenues, up from 5.4% a year ago [3][9] - EBITDA reached USD 520 million, reflecting a 13.2% YoY increase in reported currency and a 19.6% increase in local currency terms [3][9] Capital Expenditure and Financial Position - Capital expenditures (Capex) for 2Q25 were USD 231 million, resulting in a capex intensity of 21.3% for the quarter [4] - Total cash and cash equivalents as of June 30, 2025, amounted to USD 1,283 million, with net debt to EBITDA at 1.32x [4][9] Outlook - The company revised its 2025 outlook, expecting local currency revenue growth of 13% to 15% and local currency EBITDA growth of 14% to 16% [5][10] - Capex intensity for 2025 is anticipated to remain within the range of 17% to 19% [5][10] Strategic Initiatives - VEON completed the third phase of its share buyback program, acquiring 722,588 ADSs for a total of USD 35 million, completing a previously announced USD 100 million buyback program [6] - The acquisition of Uklon in April 2025 marks a strategic milestone in expanding VEON's digital services footprint [8]

Core Insights - The U.S. has imposed an additional 25% tariff on Indian goods, leading to a potential total tariff of 50%, significantly impacting India's exports to the U.S. [1][2] - India's exports to the U.S. accounted for nearly 20% of its total goods exports, which reached approximately $434 billion in the fiscal year ending March 2025 [2][3] - The tariffs are expected to reduce India's GDP growth from a forecasted 7% to around 6% for the current and next year [3] Engineering Goods - Engineering goods are India's largest exports to the U.S., totaling nearly $117 billion, with about $19.16 billion (16%) sold to the U.S. [4] - The sector is already facing a 50% tariff on steel exports, which could worsen the outlook for other engineering segments [5] Gems and Jewelry - The gems and jewelry sector contributes 7% to India's GDP and employs around 5 million workers, with 33% of its exports directed to the U.S. [6] - Higher tariffs are seen as an additional burden on the sector, prompting calls for government support [7] Textiles and Apparels - The textiles sector employs about 45 million workers and also faces significant challenges due to the new tariffs, with 34% of its exports going to the U.S. [8][9] - The sector's competitiveness is at risk as it will no longer enjoy a significant duty differential advantage compared to other countries [9] Electronics - The electronics sector is highly exposed to U.S. tariffs, with 38% of its exports going to the U.S. [10] - India has recently become the top exporter of smartphones to the U.S., with exports of electronic goods more than doubling to $2.76 billion in March 2025 [11] Pharmaceuticals - The pharmaceutical sector, which is currently exempt from tariffs, faces potential duties that could reach as high as 250% in the future [12][13] - Exports to the U.S. reached over $10.5 billion, accounting for nearly 35% of India's total pharmaceutical shipments [13] Overall Competitiveness - India's export competitiveness is likely to be eroded over time as the U.S. can source supplies from alternative locations more easily than India can diversify its exports [15][16] - Approximately 32% of India's exports to the U.S. are currently exempt from tariffs, including electronics and pharmaceuticals [17]

Sony Pictures saw a 76% jump in operating profit for the June quarter to $129 million on revenue that grew 4% to $2.3 billion as the studio said more series deliveries in the Television Productions offset a softer theatrical release slate year-on-year for the Japanese giant’s fiscal first quarter. Television Productions saw revenue rise to $841 million from $607 million the year before when series deliveries were slowed by the impact of Hollywood strikes. Theatrical revenue fell to $132 million from $322 m ...